doi: https://www.sciencedirect.com/science/article/pii/s0002929716301987?via%3dihub<br><br><br>biallelic iars mutations cause growth retardation with prenatal onset, intellectual disability, muscular hypotonia, and infantile hepatopathy - sciencedirect<br>javascript is disabled on your browser.<br>please enable javascript to use all the features on this page.<br>function ie8click() {<br>const node = document.getelementbyid('ie8warning');<br>document.cookie = 'ie_warning_state=1';<br>node.parentnode.removechild(node);<br>}<br>please note that internet explorer version 8.x is not supported as of january 1, 2016.<br>please refer to this support page for more information.<br>&times;<br>outlinedownload pdfdownloadshareexport<h2>outline</h2><h2>figures (3)</h2><h2>tables (1)</h2><h2>extras (2)</h2>download all , 4 august 2016, pages 414-422<h1><h5>reportbiallelic iars mutations cause growth retardation with prenatal onset, intellectual disability, muscular hypotonia, and infantile hepatopathy</h1>author links open overlay panelshow moreunder an elsevier open archive synthetase deficiencies are a growing group of genetic diseases associated with tissue-specific, mostly neurological, phenotypes. in cattle, cytosolic isoleucyl-trna synthetase (iars) cause hereditary weak calf syndrome. in three unrelated  <span style="color:red" title="HPO: HP:0001510
CONF: 1" >individuals with se</span>  <span style="color:red" title="HPO: HP:0001511
CONF: 1" >vere prenatal-onset</span>  <span style="color:red" title="HPO: HP:0003577
CONF: 1" > growth retardation</span>  <span style="color:red" title="HPO: HP:0012828
CONF: 1" >,</span>  intellectual disability <span style="color:red" title="HPO: HP:0001249
CONF: 1" >,</span>  and muscular hypotonia <span style="color:red" title="HPO: HP:0001252
CONF: 1" > revealed bialleli</span>  <span style="color:red" title="HPO: HP:0001290
CONF: 1" >c mutations in iars</span>  <span style="color:red" title="HPO: HP:0001319
CONF: 1" >.</span>  studies in yeast confirmed the pathogenicity of identified mutations. two of the individuals had infantile hepatopathy with fibrosis and steatosis <span style="color:red" title="HPO: HP:0001397
CONF: 1" >,</span>  leading in one to liver failure in the course of infections <span style="color:red" title="HPO: HP:0001399
CONF: 1" >.</span>  was present in all affected individuals and supplementation with zinc showed a beneficial effect on growth in one.<br><h2>main text</h2> (arss) catalyze the of trnas by their cognate amino acid, linking amino acids with the correct triplets and ensuring the correct transformation of the genetic code to the protein level. editing activities of arss further increase translation fidelity by preventing misacylation of trnas with non-cognate amino acids. in mammals, arss can be distinguished by their cytoplasmatic or mitochondrial localization <span style="color:red" title="HPO: HP:0001427
CONF: 1" >,</span>  with only two ars in both compartments (gars and kars). in 2003, charcot marie tooth disease (cmt) type 2d (mim: ) and neuropathy <span style="color:red" title="HPO: HP:0009830
CONF: 1" >,</span>  distal hereditary motor, type va (mim: ), caused by mutations in gars (mim: , encoding glycyl-trna synthetase) were reported as the first ars-associated human disease phenotypes. since then, several clinical conditions associated with mutations in mitochondrial arss <span style="color:red" title="HPO: HP:0001427
CONF: 1" >,</span>  and cytosolic arss have been identified. clinically, most cytosolic synthetase deficiencies are associated with cmt and related neuropathies, whereas mutations in lars (mim: ) cause infantile acute liver failure syndrome type 1 (mim: ) and mutations in mars (mim: ) cause interstitial lung and liver disease (mim: ).<br>mutations in cytosolic iars (mim: ) have not yet been linked to human disease. however, a homozygous (c.235g&gt;c) in exon 3 has recently been identified as the molecular cause of weak calf syndrome in japanese black cattle. the affected calves  <span style="color:red" title="HPO: HP:0001510
CONF: 1" >exhibit prenatal-ons</span>  <span style="color:red" title="HPO: HP:0001511
CONF: 1" >et growth retardation</span>  <span style="color:red" title="HPO: HP:0003577
CONF: 1" >,</span>  severe musc <span style="color:red" title="HPO: HP:0001324
CONF: 1" >le weakness </span>  <span style="color:red" title="HPO: HP:0012828
CONF: 1" >with astasia</span>  <span style="color:red" title="HPO: HP:0020037
CONF: 1" >,</span>  and fatty degeneration of liver cells <span style="color:red" title="HPO: HP:0001397
CONF: 1" >.,</span>  <br>here we report the identification of biallelic mutation <span style="color:red" title="HPO: HP:0001510
CONF: 1" >s in iars in three unrelated individuals with a complex mul</span>  <span style="color:red" title="HPO: HP:0001511
CONF: 1" >tisystemic phenotype of prenatal-onset growth retardation (3</span>  <span style="color:red" title="HPO: HP:0003577
CONF: 1" >/3),</span>  intellectual disability (3/ <span style="color:red" title="HPO: HP:0001249
CONF: 1" >3),</span>  muscula <span style="color:red" title="HPO: HP:0001252
CONF: 1" >r hypot</span>  <span style="color:red" title="HPO: HP:0001290
CONF: 1" >onia (2/</span>  <span style="color:red" title="HPO: HP:0001319
CONF: 1" >3),</span>  and hepatopathy with fibrosis and steatosis (2/3) aswell <span style="color:red" title="HPO: HP:0000819
CONF: 1" > as diabetes mellitus a</span>  <span style="color:red" title="HPO: HP:0001397
CONF: 1" >nd</span>  sensorineu <span style="color:red" title="HPO: HP:0000365
CONF: 1" >ral hearin</span>  <span style="color:red" title="HPO: HP:0000407
CONF: 1" >g loss(1/3</span>  <span style="color:red" title="HPO: HP:0008527
CONF: 1" >).</span>  the three individuals studied originate from germany (#65269, deu), japan (#85880, jpn), and austria (#83921, aut). clinical findings are summarized in (for anthropometrical data see ).<br>table 1. genetic and clinical findings in individuals with iars mutations<br>idsexage at last visitiars mutationsaoclinical featurescdna (nm_002161.5); protein (eaw62813.1)growth retardation (sds)neurological a <span style="color:red" title="HPO: HP:0001510
CONF: 1" >nd</span>  cognitive outcomeliver function (histologic findings)other features#65269 (deu)m18.7 yearsc.[1252c&gt;t];[3521t&gt;a]; p.[arg418];[ile1174asn]prenatal (iugr)yes (5.9)moderate to severe intellectual disability, no expressive speech, spastic movement disorder (gmfcs iv), muscular hypotonia, brain mri abnormalintermittently mildly affected hepatic synthesis (no liver biopsy)strabismus, feeding through peg, esophagitis, zinc deficiency (8.5mol/l; n 1318)#85880 (jpn)f19 yearsc.[760c&gt;t];[1310c&gt;t]; p.[arg254];[pro437leu]pren <span style="color:red" title="HPO: HP:0001249
CONF: 1" >atal (iugr)yes (6.2)modera</span>  <span style="color:red" title="HPO: HP:0001511
CONF: 1" >te intellectual disability </span>  <span style="color:red" title="HPO: HP:0002342
CONF: 1" >(iq 50),</span>  motor function normalelevated alat and asat, neonatal ons <span style="color:red" title="HPO: HP:0001397
CONF: 1" >et (steatosi</span>  <span style="color:red" title="HPO: HP:0003623
CONF: 1" >s,</span>  fibrosis)sensoneurinal hearing loss (ao 5 year <span style="color:red" title="HPO: HP:0000365
CONF: 1" >s),</span>  diabetes mellitus (ao 16 year <span style="color:red" title="HPO: HP:0000819
CONF: 1" >s),</span>  epilepsy <span style="color:red" title="HPO: HP:0001250
CONF: 1" >,</span>  zinc deficiency (7.5mol/l; n 1118)#83921 (aut)m3 yearsc.[1109t&gt;g];[2974a&gt;g]; p.[val370gly];[asn992asp]prenatal (iugr)yes (6.2)moderate intellectua <span style="color:red" title="HPO: HP:0001511
CONF: 1" >l and</span>  motor disability, muscular hypotoniarecurrent liver crises triggered by infections, infantile liver failure <span style="color:red" title="HPO: HP:0001399
CONF: 1" >,</span>  neonatal ons <span style="color:red" title="HPO: HP:0001397
CONF: 1" >et (steatosi</span>  <span style="color:red" title="HPO: HP:0003623
CONF: 1" >s,</span>  fibrosis, cholestasis)pe <span style="color:red" title="HPO: HP:0000271
CONF: 1" >culiar facial d</span>  <span style="color:red" title="HPO: HP:0000291
CONF: 1" >istribution of </span>  <span style="color:red" title="HPO: HP:0000293
CONF: 1" >subcutaneous fa</span>  <span style="color:red" title="HPO: HP:0001396
CONF: 1" >t (chubby cheek</span>  <span style="color:red" title="HPO: HP:0004426
CONF: 1" >s),</span>  feeding through peg, zinc deficiency (6.1mol/l; n 1115)<br>abbreviations are as follows: m, male; f, female; ao, age of onset <span style="color:red" title="HPO: HP:0003674
CONF: 1" >;</span>  iugr <span style="color:red" title="HPO: HP:0001511
CONF: 1" >,</span>  retardation; gmfcs, gross motor function classification system; peg, percutaneous endoscopic gastrostomy; n, normal range.<br>individual #65269 (deu), a boy, was born at 38weeks gestational age to non-consanguineous german parents. birth weight and head circu <span style="color:red" title="HPO: HP:0000252
CONF: 1" >mference we</span>  <span style="color:red" title="HPO: HP:0004325
CONF: 1" >re low (we</span>  <span style="color:red" title="HPO: HP:0011451
CONF: 1" >ight 2,020 </span>  <span style="color:red" title="HPO: HP:0040195
CONF: 1" >g,</span>  3.0 sds; head circumference 29.0cm, 4.2 sds; see ). he has two healthy sisters. pregnancy was normal except for retardation. substantial psychomotor retardation, muscular hypotonia, and poor feeding were noted shortly after birth and despite alimentation by percutaneous gastroenterostomy with a , failure to thrive was very severe (at 6 years of age, body weight 10.8kg, 8.0 sds). during the first 2 to 3 years, multiple clinically sev <span style="color:red" title="HPO: HP:0012828
CONF: 1" >ere infections occurred</span>  <span style="color:red" title="HPO: HP:0032169
CONF: 1" >.</span>  at the age of 7 years, was detected in serum (8.5mol/l; normal range 1318) and zinc supplementation was begun (1mg/kg body weight/day). normalization was associated with pronounced improvement in clinical status. he had fewer infections; weight, height, and head circumference increased substantially (se <span style="color:red" title="HPO: HP:0040194
CONF: 1" >e );</span>  and both and low levels of growth horm <span style="color:red" title="HPO: HP:0000824
CONF: 1" >one-dependent factors and</span>  <span style="color:red" title="HPO: HP:0001510
CONF: 1" ></span>  normalized. also seemed to improve: the child became more alert and mobile and progressively took increasing part in various daily activities. examination at <span style="color:red" title="HPO: HP:0000750
CONF: 1" > the age of 17 </span>  <span style="color:red" title="HPO: HP:0001249
CONF: 1" >years revealed</span>  <span style="color:red" title="HPO: HP:0001344
CONF: 1" > lack of expres</span>  <span style="color:red" title="HPO: HP:0002167
CONF: 1" >sive speech wit</span>  <span style="color:red" title="HPO: HP:0002342
CONF: 1" >h moderate to </span>  <span style="color:red" title="HPO: HP:0010864
CONF: 1" >severe intellec</span>  <span style="color:red" title="HPO: HP:0012828
CONF: 1" >tual disability</span>  <span style="color:red" title="HPO: HP:0100543
CONF: 1" >,</span>  muscul <span style="color:red" title="HPO: HP:0001252
CONF: 1" >ar hyp</span>  <span style="color:red" title="HPO: HP:0001290
CONF: 1" >otonia</span>  <span style="color:red" title="HPO: HP:0001319
CONF: 1" >,</span>  and bilateral spasticity (gross motor function classification system level i <span style="color:red" title="HPO: HP:0001257
CONF: 1" >v).</span>  however, he understood commands, interacted with others, and performed some activities. weight and height had become nearly normal (2.8 sds resp. 1.6 sds), whereas microcephaly was <span style="color:red" title="HPO: HP:0000252
CONF: 1" > still pronounced (5.1 sd</span>  <span style="color:red" title="HPO: HP:0011451
CONF: 1" >s).</span>  showed white matter changes consistent with hypomyelination ().<br>individual #85880 (jpn), a girl, was born at 38weeks gestational age, the third child of non-consanguineous japanese parents. a brother is healthy. a sister has  <span style="color:red" title="HPO: HP:0001249
CONF: 1" >mild intellect</span>  <span style="color:red" title="HPO: HP:0001256
CONF: 1" >ual disability</span>  <span style="color:red" title="HPO: HP:0012825
CONF: 1" >.</span>  birth weight and head circum <span style="color:red" title="HPO: HP:0000252
CONF: 1" >ference were</span>  <span style="color:red" title="HPO: HP:0011451
CONF: 1" > low (1,564 </span>  <span style="color:red" title="HPO: HP:0040195
CONF: 1" >g,</span>  4.1 sds; 29cm, 3.5 sds). pregnancy was normal except for intrauterine  <span style="color:red" title="HPO: HP:0001510
CONF: 1" >growth retardation</span>  <span style="color:red" title="HPO: HP:0001511
CONF: 1" >.</span>  at the age of 4days, mildly activities (alat, asat) and a normal to slightly reduced were observed. these spontaneously improved until 6 years of age. liver biopsy at 2 years of age showed steatosis and <span style="color:red" title="HPO: HP:0001397
CONF: 1" ></span>  portal-tract fibrosis with evidence of accelerated hepatocyte turn-over in ab <span style="color:red" title="HPO: HP:0006580
CONF: 1" >sence of other usual histopathologic features of hepatitis or steatohepatitis</span>  <span style="color:red" title="HPO: HP:0012115
CONF: 1" > ().</span>  the girl had global developmental delay (sitting at 15months of ag <span style="color:red" title="HPO: HP:0001263
CONF: 1" >e,</span>  walking at 2 years of age). at the age of 5 years, severe  <span style="color:red" title="HPO: HP:0000365
CONF: 1" >sensorin</span>  <span style="color:red" title="HPO: HP:0000407
CONF: 1" >eural he</span>  <span style="color:red" title="HPO: HP:0008527
CONF: 1" >aring lo</span>  <span style="color:red" title="HPO: HP:0008625
CONF: 1" >ss was d</span>  <span style="color:red" title="HPO: HP:0012714
CONF: 1" >iagnosed</span>  <span style="color:red" title="HPO: HP:0012828
CONF: 1" >.</span>  body growth was retarded (with do <span style="color:red" title="HPO: HP:0000824
CONF: 1" >cumented growth hormone deficienc</span>  <span style="color:red" title="HPO: HP:0001510
CONF: 1" >y).</span>  growth hormone therapy between the ages of 3 4/12 years and 14 years resulted in normalization of growth. she had an unexplained episode of and two episodes o <span style="color:red" title="HPO: HP:0001250
CONF: 1" >f afebrile gen</span>  <span style="color:red" title="HPO: HP:0002069
CONF: 1" >eralized tonic-</span>  <span style="color:red" title="HPO: HP:0002169
CONF: 1" >clonic seizure</span>  <span style="color:red" title="HPO: HP:0002197
CONF: 1" >s for a few mi</span>  <span style="color:red" title="HPO: HP:0010818
CONF: 1" >nutes at 14 and</span>  <span style="color:red" title="HPO: HP:0011169
CONF: 1" ></span>  16 years. electroencephalograms were unremarkable and no antiepileptic drug therapy was initiated. insulin-dependent diabetes mellitus  <span style="color:red" title="HPO: HP:0000819
CONF: 1" >was diagnosed at 16 years of age and</span>  <span style="color:red" title="HPO: HP:0100651
CONF: 1" ></span>  insulin therapy was started. brain mri was normal at the age of 16 years. at this writing, she is 21 years old and has mild to mo <span style="color:red" title="HPO: HP:0001249
CONF: 1" >derate intelle</span>  <span style="color:red" title="HPO: HP:0001256
CONF: 1" >ctual disabili</span>  <span style="color:red" title="HPO: HP:0002342
CONF: 1" >ty (verbal iq 4</span>  <span style="color:red" title="HPO: HP:0012825
CONF: 1" >7,</span>  performance iq 50). she has no microcephaly. liver function is normal. recurrent infection is not a problem.<br>individual #83921 (aut), a boy, was born at 38+4weeks gestational age to non-consanguineous austrian parents. birth weight and head circumfe <span style="color:red" title="HPO: HP:0000252
CONF: 1" >rence were bo</span>  <span style="color:red" title="HPO: HP:0011451
CONF: 1" >th low (2,700 </span>  <span style="color:red" title="HPO: HP:0040195
CONF: 1" >g,</span>  1.6 sds; 30cm, 3.8 sds). pregnancy was normal except for intrauterine  <span style="color:red" title="HPO: HP:0001510
CONF: 1" >growth retardation</span>  <span style="color:red" title="HPO: HP:0001511
CONF: 1" >.</span>  at the age of 3weeks, jaundice became apparent and <span style="color:red" title="HPO: HP:0000952
CONF: 1" ></span>  conjugated hyp <span style="color:red" title="HPO: HP:0002904
CONF: 1" >erbilirubinemia</span>  <span style="color:red" title="HPO: HP:0002908
CONF: 1" >,</span>  mildly elevated alat and <span style="color:red" title="HPO: HP:0012825
CONF: 1" ></span>  asat, but normal gt and mild hypoalbuminemia were identified. liver biopsy found non-specific changes labeled as neonatal hepatitis. jaundice spontaneously disappeared at the age of 5months <span style="color:red" title="HPO: HP:0000952
CONF: 1" >.</span>  in the second year of life, three episodes of marked co <span style="color:red" title="HPO: HP:0002904
CONF: 1" >njugated hyperbilirubinemia</span>  <span style="color:red" title="HPO: HP:0002908
CONF: 1" >,</span>  moderate , markedly elevated alat and asat, but normal gt were encountered in the context of a gastrointestinal and two respiratory infections. liver biopsy at 14months of age showed cholestasis <span style="color:red" title="HPO: HP:0001396
CONF: 1" >,</span>  steatosis with steatohepatitis <span style="color:red" title="HPO: HP:0001397
CONF: 1" >,</span>  portal-tract fibrosis with bridging in a biliary rather than post-necrotic pattern <span style="color:red" title="HPO: HP:0006580
CONF: 1" >,</span>  and evidence of accelerated hepatocyte turn-over (). at the age of 2 years, an upper respiratory tract infection wasaccompanied by acute liver failure (conjugated 10.2mg/dl, normal &lt; 0.3; alat 360u/l, asat 1,700u/l, normal &lt; 50; gt 16u/l, normal &lt; 21; inr 2.7, normal &lt; 1.2) complicated by candida sepsis an <span style="color:red" title="HPO: HP:0100806
CONF: 1" >d</span>  requiring intensive-care support. after recovery, he had an episode of prolonged conjugated hyperbiliru <span style="color:red" title="HPO: HP:0002904
CONF: 1" >binemia with low serum gt associated with an infection</span>  <span style="color:red" title="HPO: HP:0002908
CONF: 1" >.</span>  after recovery from infections, levels ranged from low to normal and coagulation parameters normalized. during episodes of liver dysfunction <span style="color:red" title="HPO: HP:0001410
CONF: 1" >,</span>  the boy appeared to benefit from a high-calorie diet. alimentation was generally difficult: despite high-calorie , weight and height remained below the 3 percentile and at 2 years of age (height 6.2 sds, weight 3.5 sds, head circumference 4.4 sds) a percutaneous gastrostomy was placed. on high-calorie stomal feeding the boy throve better, with improved motor skills, but vomiting was a problem <span style="color:red" title="HPO: HP:0002013
CONF: 1" >.</span>  zinc deficiency was diagnosed at 2 6/12 years of age and zinc supplementation was started (12mg/kg body weight/day). zinc levels fluctuated markedly (minimum 6.1mol/l) but tended to be slightly below the normal range despite supplementation. supplementation with (200mg/kg/day) also was started and alimentation increased. the boy has thereafter appeared less susceptible to infection <span style="color:red" title="HPO: HP:0002719
CONF: 1" >,</span>  with better development. psychomotor development was delayed <span style="color:red" title="HPO: HP:0001263
CONF: 1" >;</span>  at the age of 2 years, the child performed at the level of a 12-month-old infant. no abnormality was identified on brain mri at the age of 2 3/12 years. at this writing, the boy is 3.5 years old. he is short (5.0 sds) and microcepha <span style="color:red" title="HPO: HP:0000252
CONF: 1" >lic (3.3 sd</span>  <span style="color:red" title="HPO: HP:0011451
CONF: 1" >s),</span>  but bmi is normal (+1.0 sds).<br>in all three individuals, a was suspected clinically and complexes weremeasured in muscle (subjects deu and aut), liver (subject aut), and/or fibroblasts (subjects deu and jpn) (see ). activities of complex i appeared to be decreased in the three subjects in at least one tissue, whereas activity of complex iv was decreased in one. thorough clinical and metabolic investigations were without specific findings in all cases. transient elevations of concentrations were found. however, plasma lactate was also repeatedly normal in all individuals and brain (mrs), performed in subjects deu and aut at the age of 17 and 2 years, showed no lactate peaks.<br>informed consent to participate in the study was obtained from all affected individuals or their parents in case of minor study participants. the study was approved by the ethics committees of the university hospital heidelberg, the technische universitat munchen, the jikei university school of medicine, chiba childrens hospital and saitama medical university, and the medical university of innsbruck. performed on genomic dna from individual #65269 (deu) did not identify likely clinically relevant variants in genes previously associated with the observed clinical phenotype or a mitochondrial disorder., a search for homozygous or potentially compound heterozygous rare variants (maf &lt; 0.1% in 7,000 in-house , 1000 genomes study) prioritized the five genes prob1, ubr2 (mim: ), iars, plxnb3 (mim: ), and dusp21 (mim: ). given the overlap of clinical features of the investigated individual with the phenotypic spectrum of other ars defects, we considered iars a strong candidate. results of two independent exome sequencing studies that revealed biallelic iars variants in two unrelated individuals from austria and japan with phenotypic features like those in the german boy supplied further evidence for a causal association of biallelic iars variants with the disease presentation. all six identified iars variants were confirmed by . carrier testing confirmed a compound heterozygous state of theiars variants (). except for the variant c.1252c&gt;t, which was detected three times in a heterozygous state, none of the iars variants (c.760c&gt;t, c.1109t&gt;g, c.1310c&gt;t, c.2974a&gt;g, and c.3521t&gt;a) was listed in &gt;120,000 alleles of the exome aggregation consortium (exac) server (12/2015). all the missense mutations change evolutionarily conserved amino acid residues () and are accordingly predicted to be damaging (polyphen-2 and sift). immunoblotting analysis of fibroblast cell extracts from all three affected individuals showed reduced levels of iars protein only for subject #65269 (deu; see ). of formalin-fixed, paraffin-embedded archival liver-biopsy material (jpn, aut) found no marking for iars in one (jpn) and normal marking in the other (aut; ). four of the six mutations lie in the first half of the gene, in close proximity to the ilers core domain ().<br>figure1. iars variants and gene structure<br>(a) pedigrees of the three families with recessive inherited mutations in iars.<br>(b) structure of iars with known conserved protein domains in the gene product and localization and conservation of amino acid residues affected by mutations identified in the three families as well as by the orthologous-gene mutation associated with the weak calf syndrome. intronic regions are not drawn to scale. coloring in the represents the identity of amino acid residues.<br>to evaluate the functional relevance of identified iars variants, we made use of a tet-off yeast model. in the tet-ils1 strain, expression of ils1, the<br>of human iars, can be negatively regulated by addition of doxycycline to the growth medium. the strain shows normal growth under standard conditions (). reduced expression of ils1 resulted in considerable growth impairment <span style="color:red" title="HPO: HP:0001510
CONF: 1" >;</span>  however, this phenotype was fully rescued by expression of the human wild-type iars cdna (, first two lines) providing an invivo assay to evaluate mutant alleles. iars cdnas carrying the different variants were cloned into the low-copy vector pyx122 (novagen) and growth was compared to that of cells transformed with a wild-type copy of iars or with the empty vector.<br>figure2. yeast studies<br>spot assay and growth curves of tet-ils1 strain, transformed with the low copy vector pyx122 (novagen) containing different mutated versions of human iars cdna encoding the protein products hsiars wt, pyx122:hiars; hsiars v79l, pyx122:hiars; hsiars i1174n, pyx122:hiars; hsiars r418, pyx122:hiars; hsiars r254, pyx122:hiars; hsiars p437l, pyx122:hiars; hsiars v370g, pyx122:hiars; and hsiars n992d, pyx122:hiars. empty vector pyx, pyx122, was used as a negative control. decreasing numbers of yeast cells (5 10, 5 10, 5 10, 5 10, 5 10) were spotted onto plates containing drop-out medium (sc-his). growth curves were obtained in liquid cultures with sc-his medium by monitoring od600. downregulation of yeast ils1 was induced by addition of 50mg/ml doxycycline.<br>(a) expression of the different iars wt and mutant constructs in the tet-ils1 strain did not show any negative effect on growth.<br>(b) downregulation of ils1 led to failure in growth that could be rescued by expression of human wild-type iars. each affected individual carries one loss-of-function allele in combination with one allele that displays residual activity as measured by growth. transformation with a construct encoding the variant associated with the perinatal weak calf syndrome resulted in partial rescue of the growth defect.<br>(c) growth in liquid culture. cells grown overnight were inoculated into fresh medium containing doxycycline. od600 = 0.1; growth monitored at 30c.<br>(d) after 12.5hr of growth, expressed as percentage of wt. all variants significantly impaired the growth rate (wilcoxon tes <span style="color:red" title="HPO: HP:0001510
CONF: 1" >t,</span>  p &lt; 0.05).<br>representative data are shown.<br>without addition of doxycycline, the transformed yeast strains grew like the positive control. upon downregulation of the yeast iars ortholog, no growth rescue was observed in yeast transformed with empty vector (negative control), plasmids encoding the two iars loss-of-function variants c.1252c&gt;t (p. arg418) (#65269, deu) and c.760c&gt;t (p. arg254) (#85880, jpn), or a plasmid encoding the missense variant c.2974a&gt;g (p. asn992asp) (#83921, aut). an intermediate growth phenotype was obtained by expression of the four missense variants c.235g&gt;c (p. val79leu) (not encountered in any ; the ortholog of that in iars in cattle, which underlies weak calf syndrome), c.3521t&gt;a (p. ile1174asn) (#65269, deu), c.1310c&gt;t (p. pro437leu) (#85880, jpn), and c.1109t&gt;g (p. val370gly) (#83921, aut); the last displayed the mildest, but significant, growth impairment <span style="color:red" title="HPO: HP:0001510
CONF: 1" > ().</span>  hence, each affected human individual is compound heterozygous for an iars loss-of-function allele and an allele with significantly reduced but some remaining functionality, similar to the allele causing weak calf syndrome. treatment with zinc appeared beneficial in subject #65269 (deu), possibly due to zinc deficiency or to zinc dependence of iars activity, as shown for the e.coli ortholog. supplementation using a wide range of zinc concentrations did not improve yeast growth, permitting argument that zinc has no direct effect on iars activity.<br>to gain further insight into the expression pattern of iars and its role for , we undertook and (mo) knockdown of iars in zebrafish. iars is conserved in zebrafish and shares 74% homology to the human protein. the expression of iars is ubiquitous in zebrafish during early embryonic development. it localizes to the and developing brain regions after , especially in the tectum region of the brain, pineal gland, and hindbrain (). to assess iars function, two splice-blocking mos specific to iars were injected into zebrafish embryos. mo specificity was validated by and injection of 5-bp-mismatch mos ( and data not shown). upon iars downregulation, embryonic development is generally delayed <span style="color:red" title="HPO: HP:0001263
CONF: 1" >,</span>  with embryos exhibiting altered brain configuration and severe shortening of the posterior body axis <span style="color:red" title="HPO: HP:0012828
CONF: 1" > ().</span>  the observed phenotype had a high consistency of about 85% for both mos. notably, the knockdown resulted in a concentration-dependent high level of lethality. embryos injected with 0.5ng and 1ng mo targeting exon 32 showed 40% (n = 35) and 80% (n= 95) lethality rates, respectively, while 80% and 85% of embryos died upon injection ofthesame concentrations of mo targeting exon 18 (n0.5ng = 37 and n1ng = 87). lethality rate was decreased to 41% (n = 93) by addition of human iars mrna, confirming the mo targeting exon 18 specificity and, at the same time, suggesting an evolutionarily conserved role for iars in embryonic development. as in yeast, zinc treatment did not result in a phenotypic rescue (data not shown). overall the experiments performed in this animal model suggest an important role for iars in embryogenesis. downregulation of iars causes high lethality, with surviving embryos exhibiting a severe and <span style="color:red" title="HPO: HP:0012828
CONF: 1" ></span>  consistent brain phenotype and a shortening of the body axis reminiscent of the human phenotype.<br>figure3. and knockdown of iars in zebrafish<br>zebrafish were maintained and embryos were staged as described. embryos older than 24hr after (hpf) were treated with 0.0003% phenylthiourea (sigma) to inhibit pigment synthesis and fixed in 4% paraformaldehyde (pfa) previous to insitu hybridization. the insitu hybridization protocol was adapted using specific probes for the iars mrnas. the mos usedwere splice blocking and 5-bp-mismatch control mos, designed and synthesized by gene tools (exon 18 mo: 5-atgtgtggtttgttttctcaccgta-3, exon 18 5-bp-mismatch 5-atatgtagtttattttctaaccata-3; exon 32 mo: 5-accgtctgacagcagaacacacaga-3, exon 32 5-bp mismatch: 5-aacgtctaacagaagaacaaacaaa-3). single-cell stage embryos were injected with 0.5ng of mo and maintained at 28c until the desired developmental stage was attained.<br>lateral views with anterior to the left at developmental stages indicated.<br>(a) in situ hybridization for iars mrna at 13 hpf and sense mrna control. iars expression localizes predominantly to the and developing brain regions. the arrow indicates midbrain expression.<br>(b) 25 hpf. iars insitu (left), arrows indicate tectum (blue), cerebellum (black), and somites (red). sense control (right) shows no signal.<br>(c) 48 hpf. iars is specifically expressed in the tectum region of the brain (blue), as well as in the pineal gland (green) and hindbrain (black).<br>(d) mo-injected zebrafish embryos at 26 hpf are shown. knockdown of iars yields retarded development <span style="color:red" title="HPO: HP:0001263
CONF: 1" >,</span>  brain deformity, as indicated by the arrow to the midbrain region, and severe shortening of the body axis <span style="color:red" title="HPO: HP:0012828
CONF: 1" >,</span>  as highlighted by the double head arrows. left, control embryo; middle, zebrafish injected with mo targeting exon 18; right, zebrafish injected with mo targeting exon 32.<br>mutations in iars recently have been identified as underlying weak calf syndrome in japanese black cattle. the phenotype of the calf disorder strikingly resembles that of the three probands of this study <span style="color:red" title="HPO: HP:0002981
CONF: 1" >.</span>  body weight in six affected calves was between 30% and 70% of that of age-matched control calves. we tested whether (oxphos) activity is decreased in affected calves, as findings varied within our patient cohort. oxphos activities in muscle, liver, and fibroblasts of affected calves (n = 6) were normal compared with controls (n = 3; see ). thus, oxphos dysfunction is not directly linked to mutations in iars in calves. we also determined in 13 affected calves and 20 healthy calves. zinc levels did not differ between the two groups (). hence it is likely that reduced zinc levels and impaired oxphos activities are not directly related to iars mutations.<br>our genetic and experimental findings provide evidence that mutations affecting functionally conserved domains in iars cause a multisystem phenotype in man including severe growth retardation with prenatal onset, intellectual disability, muscular hypotonia, and infantile hepatopathy.<br>all three individuals presented in this study share principal clinical features, but phenotypes vary. the neurological phenotype in individual #65269 (deu) is severe, including absence of expressive speech, spasticity, pronounced white matter deficit, and severe microcephaly, whereas individual #85880 (jpn) has moderate intellectual disability without motor dysfunction and with normal findings on brain mri. it cannot be excluded that the intellectual disability of individual #85880 (jpn) is modified by another cause than iars mutations, because her sister, who did not harbor the identified pathogenic iars variants, is also affected by intellectual disability. however, in the families of individuals #65269 (deu) and #83921 (aut), family histories for intellectual disability are unremarkable.<br>liver function was basically normal in individual #65269 (deu), whereas infantile hepatopathy (leading to liver failure in one occasion) was present in the other two probands, with steatosis and portal-tract fibrosis. liver biopsy of individual #83921 (aut) additionally displayed cholesta <span style="color:red" title="HPO: HP:0001396
CONF: 1" >sis.</span>  among 107 rare or private variants identifiedinthe exome of this subject was a heterozygous c.1460g&gt;a (p. arg487his) change in (mim: , : ), encoding bile salt export pump (bsep). however, immunostaining of liver-biopsy material found normal bsep marking. a homozygous mutation affecting the same , yielding p. arg487pro, has been identified in a subject with progressi <span style="color:red" title="HPO: HP:0001396
CONF: 1" >ve familial intrahepatic cholestasis type 2 (mi</span>  <span style="color:red" title="HPO: HP:0001406
CONF: 1" >m:</span>  ). heterozygous abcb11 mutations are implicated as pred <span style="color:red" title="HPO: HP:0001396
CONF: 1" >isposing to intrahepatic cholestasis of pregnancy and</span>  <span style="color:red" title="HPO: HP:0001406
CONF: 1" ></span>  to transient neonatal cholestasis <span style="color:red" title="HPO: HP:0001396
CONF: 1" >.</span>  the abcb11 variant identified in individual #83921 (aut) may contribute to greater severity of liver disease, including cholestasis, in him than in the other individuals with compound heterozygous iars mutations and no rare variants in abcb11.<br>an essential role of iars is underlined by the fact that none of the human subjects have two loss-of-function alleles (the same holds for affected calves, which are homozygous for a single substitution mutation) and by the mainly lethal, severe phenotype of mo knockdown zebrafish. the pathomechanism of iars deficiency is not yet understood. although reduced growth could be explained by altered global translational performance <span style="color:red" title="HPO: HP:0001510
CONF: 1" >,</span>  the pathomechanism of organ-specific signs is likely to be more complex. given the ubiquitous presence and vital importance of arss in all cells of archae, bacteria, and , it is remarkable that mutations in arss cause considerably distinct clinical pictures with tissue-specific phenotypes in humans., , apart from aminoacylation and editing activity, the so-called canonical functions of arss, some arss exhibit non-canonical activities in vertebrates. these include translational control, , , and modulation of cell migration, , inflammation, and tumorigenesis., iars also is part of a multi-synthetase complex (msc), which is organized by nine cytoplasmic arss and the three synthetase-interacting aimp1, aimp2, and aimp3., tissue specificity has been speculatively linked to such non-canonical functions or to involvement in the msc. interestingly, deficiencies of lars and mars also are known to cause hepatopathy,, and these enzymes also are part of the msc. to propose a role of msc dysfunction in hepatobiliary disease thus lies near at hand, perhaps through accumulation of mis-folded proteins <span style="color:red" title="HPO: HP:0001658
CONF: 1" >,</span>  with in consequence, due to incorrect editing of amino acids. an important role for iars in zebrafish brain development is consonant with the abnormalities of brain function in the subjects of this study.<br>regarding the mri findings in cytosolic ar <span style="color:red" title="HPO: HP:0012443
CONF: 1" >s,</span>  several open questions remain. the mild supratentorial white matter t2-hyperintensity in subject #65269 (deu) is consistent either with a complex pattern of hypomyelination with a normal signal of subcortical, late myelinating white matter or with white matter changes secondary to neurodegeneration; his visually low resonances in the quantitiati <span style="color:red" title="HPO: HP:0000505
CONF: 1" >ve mrs are also consistent with hypomyelination</span>  <span style="color:red" title="HPO: HP:0003429
CONF: 1" >.</span>  the presumed hypomyelination may be compared with individuals with mutations in dars (mi <span style="color:red" title="HPO: HP:0003429
CONF: 1" >m:</span>  ),, whereas microcephaly is reminiscent of the phenot <span style="color:red" title="HPO: HP:0000252
CONF: 1" >ype seen in individuals with mutations in qars (mi</span>  <span style="color:red" title="HPO: HP:0011451
CONF: 1" >m:</span>  ). a simplified gyral pattern is not apparent, however, in the individuals with mutations in iars. the beneficial effect of zinc supplementation observed in human subjects could not be demonstrated in the yeast or zebrafish models. therefore, iars seems to be independent of zinc levels and the beneficial effect of zinc supplementation is likely compensating secondary zinc deficiency. however, zinc has been proposed to interact with the active site of iars and to be required for normal cell growth. a role for zinc, especially in editing , has been demonstrated for other arss, including alanyl-, seryl-, and threonyl-trna synthetase., , , the cause of zinc deficiency as observed in all our three probands remains unresolved, but could be explained by chronic liver d <span style="color:red" title="HPO: HP:0001392
CONF: 1" >isease at least in individuals aut and</span>  <span style="color:red" title="HPO: HP:0011010
CONF: 1" ></span>  jpn, because chronic liver disease is known <span style="color:red" title="HPO: HP:0001392
CONF: 1" > to be associated with zinc deficiency</span>  <span style="color:red" title="HPO: HP:0011010
CONF: 1" >.,</span>  <br>in recent years, whole-exome sequencing studies haverevealed various causes of infantile liver failure with partly specific clinical phenotypes <span style="color:red" title="HPO: HP:0001399
CONF: 1" >,</span>  including mutations in lars, nbas (mim: ),, scyl1 (mim: ), and now iars. precise genetic and clinical phenotyping is crucial for both understanding these diseases and for suspecting and diagnosing them in the clinical setting. this study delineates mutations in iars as underlying a multisystemic disease affecting mainly growth, brain, and liver. for reasons yet to be determined, this disease is associated with zinc deficiency and can be palliated by zinc supplementation.<br><h2>acknowledgments</h2>we would like to thank the families for their collaboration. the authors thank caterina terrile, masakazu kohda, and yoshihito kishita for excellent technical and bioinformatical assistance, dr.kai hell for providing the tet-ils1 yeast strain and pyx122 plasmid, and dr. takako yoshioka for providing a liver-biopsy specimen from individual #85880 (jpn). the authors also thank dr. shigeru toyoda and dr. takahiro tahara for referral of subject materials and dr. m. meissl, who attends individual #83921 (aut). this work was supported by the german bundesministerium fur bildung und forschung (bmbf) through the e-rare project genomit (01gm1207) and the german network for (mitonet; 01gm1113c). t. b. h. was supported by the bmbf through the juniorverbund in der systemmedizin mitomics (fkz 01zx1405c) and h. p. by eu fp7 mitochondrial european educational training project (317433) a <span style="color:red" title="HPO: HP:0001427
CONF: 1" >nd</span>  eu horizon2020 collaborative research project sound (633974). this work was further supported by a grant of the practical research project for rare/intractable diseases from japan agency for medical research and development (amed) to k. m., the innovative cell biology by innovative technology (cell innovation program) from the ministry of education, culture, sports, science and technology (mext), japan to y. o.; the support project and a grant of strategic research center in private universities from mext, japan to saitama medical university research center for genomic medicine; and the grant-in-aid (27008b) for japan science and technology research promotion program for agriculture, forestry, fisheries, and food industry to d. w. for research on affected japanese calves.<br><h2>supplemental data</h2>download all supplementary files included with this articledocument s1. figures s1s6 and tables s1s3. <br>document s2. article plus supplemental data.<br><h2>web resources</h2><br>recommended articlesciting articles (30)<h2>references</h2> 2016 american society of human genetics.<h2>recommended articles</h2>12next<h2>citing articles (30)</h2><h2>article metrics</h2><h5>citations</h5><h5>captures</h5><h5>social media</h5>we use cookies to help provide and enhance our service and tailor content and ads. by continuing you agree to the .<br>copyright 2020 elsevier b. v. or its licensors or contributors. sciencedirect is a registered trademark of elsevier b. v.<br>sciencedirect is a registered trademark of elsevier b. v.<br>